The National Institutes of Health (NIH) in the US has granted 13 two-year awards of approximately $15m per year to develop three-dimensional (3D) microphysiological system platforms called tissue chips that will model human disease.
Intended to cover the first phase of a five-year programme, the NIH grant awardees include various organisations such as Brigham and Women’s Hospital, Columbia University, Harvard University, and the University of California.
Go deeper with GlobalData
Launched in 2012 by the NIH National Centre for Advancing Translational Sciences (NCATS), the tissue chip programme aims to develop the platforms for testing drug safety and toxicity through a quick and effective approach.
The tissue chips are designed to support living cells and human tissues while imitating the biological functions of human organs and systems.
It is expected that the research will allow better insights into disease mechanisms and enable accurate prediction of patient response to specific drugs.
See Also:
As the chips can be used to create a human body-on-a-chip, investigational drugs and therapeutic agents can be evaluated across the entire body before proceeding to clinical trials.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataNCATS director Christopher Austin said: “The goal is for these tissue chips to provide more accurate platforms to understand diseases, and to be more predictive of the human response to drugs than current research models, thereby improving the success rate of candidate drugs in human clinical trials.”
The new Tissue Chip for Disease Modelling and Efficacy Testing awards will be used to study numerous common and rare diseases, including rheumatoid arthritis, arrhythmogenic cardiomyopathy, as well as human influenza A viral infection.
The second phase of the programme will involve collaboration between researchers and pharmaceutical firms to further assess the validated disease models for evaluation of drug efficacy.
Image: This lung-on-a-chip serves as an accurate model of human lungs to test for drug safety and efficacy. Photo: courtesy of Wyss Institute for Biologically Inspired Engineering, Harvard University, Massachusetts, US.
